About the Authors

Ka-Man Venus Lai

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

Guochun Gong

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

Amanda Atanasio

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

José Rojas

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

Joseph Quispe

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

Julita Posca

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

Derek White

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

Mei Huang

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

Daria Fedorova

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

Craig Grant

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

Lawrence Miloscio

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

Gustavo Droguett

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

William T. Poueymirou

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

Wojtek Auerbach

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

George D. Yancopoulos

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

David Frendewey

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

John Rinn

david.valenzuela@regeneron.com (DV); john_rinn@harvard.edu (JR)

Affiliations Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts, United States of America, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America

David M. Valenzuela

david.valenzuela@regeneron.com (DV); john_rinn@harvard.edu (JR)

Affiliation VelociGene, Regeneron Pharmaceuticals, Inc., Tarrytown, New York, United States of America

Competing Interests

K-MVL, GG, AA, J. Rojas, JQ, JP, DW, MH, D. Fedorova, CG, LM, GD, WTP, WA, GDY, DF, DMV are employees of VelociGene, Regeneron Pharmaceuticals, Inc. A patent application has been filed relating to this work, title: LincRNA-deficient non-human animals and application No: US 14/454,464 and PCT/US2014/050178. There is no product in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: K-MVL WA D. Frendewey GDY J. Rinn DMV. Performed the experiments: GG AA J. Rojas JQ JP DW MH D. Fedorova CG LM GD WTP. Analyzed the data: K-MVL GG AA J. Rojas JQ JP DW MH D. Fedorova CG LM GD WTP WA D. Frendewey DMV. Wrote the paper: K-MVL GG D. Frendewey DMV.